AVI BioPharma, Inc. Provides Update On Hepatitis C Virus Clinical Trial Status

PORTLAND, Ore.--(BUSINESS WIRE)--April 20, 2006--AVI BioPharma, Inc. (Nasdaq:AVII - News), today issued an update on the status of its multicenter study in patients with chronic active hepatitis C virus (HCV) infection. The trial is designed to assess the safety, tolerability, pharmacokinetics (PK) and viral response to treatment with AVI's proprietary NEUGENE® antisense compound AVI-4065 among healthy volunteers and patients with HCV.

Back to news